Teleconference – H1 2018

August 2018
This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Lundbeck undertakes no duty to update forward-looking statements.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with products that are prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the products are currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.
Key product growth drives top and bottom line

- **Revenue**: Up 9% (14% in L.C.) to DKK 9.3 billion in H1 2018
- **Hedging**: Contributed DKK 277 million
- **Key products**: Up 21% to DKK 5.1 billion representing 55% of revenue
- **EBIT**: Up 46% to DKK 3.0 billion. EBIT margin significantly improved to 32.4%, but positively impacted by hedging gains
- **EPS**: Up 83% to DKK 11.07
- **FY2018**: Guidance revised

---

# Revenue (DKKm)

<table>
<thead>
<tr>
<th></th>
<th>H1 2017</th>
<th>H1 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Products*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key products*</td>
<td>0</td>
<td>8,000</td>
</tr>
</tbody>
</table>

# EPS (DKK)

<table>
<thead>
<tr>
<th></th>
<th>H1 2017</th>
<th>H1 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+9%</td>
<td>+83%</td>
</tr>
</tbody>
</table>

* Includes Other revenue and effects from hedging
* Abilify Maintena, Brintellix/Trintellix, Northera, Onfi and Rexulti
Solid revenue growth of 9% to DKK 9.3 billion in H1 2018 – in local currencies growth reached 14%

Key products* grew by DKK 874 million or 21% (33% in L.C.) with all products showing double digit growth in H1 2018

Both North America and International Markets see significant currency headwind

Growth in all regions in local currencies

Largest markets are the U.S., Canada, China, France, Italy, Japan and Spain

Key product* revenue (DKKm)

Revenue distribution** (regional split)

*) Ability Maintena, Brintellix/Trintellix, Northera, Onfi and Rexulti

**) Excluding Other revenue and effects from hedging
North America grew 1% driven by Trintellix, Rexulti, Northera and Onfi – currency headwind had significant negative impact

- North America grew 1% (14% in L.C.) to DKK 5,287 million in H1 2018
- Key products# grew 19% and constituted 80% of revenue in H1 2018
- For FY2018, North America is expected to show growth in local currencies despite LOE on Onfi towards the end of the year

North America revenue (DKKm)

* Excluding Other revenue and effects from hedging

North America’s contribution*)

* Abilify Maintena, Northera, Onfi, Rexulti and Trintellix

*) Excluding Other revenue and effects from hedging
International Markets grew 3% in H1 2018 – up 11% in local currencies

- International Markets increased 3% (11% in L.C.) to DKK 1.9 billion in H1 2018
- Positive impact from stocking of DKK ~150 million
- Key products grew by 23% and constituted 14% of sales
- Market exclusivity for Lexapro extended by two years in Japan
- Main markets are Brazil, China, Japan and South Korea
- For FY2018, International Markets is expected to show growth in local currencies

International Markets revenue (DKKm)

International Markets’ contribution*)

*) Abilify Maintena, Brintellix and Rexulti

*) Excluding Other revenue and effects from hedging
Europe grew 6% in H1 2018 driven by Abilify Maintena and Brintellix – up 7% in local currencies

- Europe grew 6% to DKK 1.5 billion in H1 2018
- Key products grew 27% and constituted 42% of sales
- Largest markets are France, Italy and Spain
- Continued strong performance for Brintellix, especially in France, Italy and Spain
- Profitability significantly improved
- Rxulti approved in Europe with launch commencing in H1 2019
- For FY2018, Europe is expected to show growth in local currencies

Europe revenue (DKKm)

Europe’s contribution*)

*) Excluding Other revenue and effects from hedging
Brintellix/Trintellix grew 26% to DKK 999 million in H1 2018 – in local currencies the growth was 36%

- **North America** grew by 20% (34% in L.C.) to DKK 542 million
- **Europe** and **International Markets** grew 33% (40% in L.C.) combined to DKK 457 million
- Largest markets are the U.S., Brazil, Canada, France, Italy, and Spain
- Growth mainly driven by France, Italy, Spain and the U.S.
- Brintellix continues to gain both volume and value share
- **PDUFA** on 21 October regarding TESD in patients with depression

**Brintellix/Trintellix** (DKKm)

<table>
<thead>
<tr>
<th>Q2.17</th>
<th>Q2.18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe + Int. Markets</td>
<td>North America</td>
</tr>
</tbody>
</table>

**Total Rx count** (U.S. retail)

Source: Symphony Health Solutions/Bloomberg (monthly data ending 6/2018)

*PDUFA: Prescription Drug User Fee Act (FDA). TESD: Treatment-Emergent Sexual Dysfunction*
Rexulti grew 28% to DKK 752 million in H1 2018 – in local currencies the growth was 44%

- Rexulti approved in Europe
- Recently also approved in Honduras and Saudi Arabia
- Rexulti has 11.3% value share (U.S.)
- Third study in AAD commenced
- Pivotal programme in bipolar mania to conclude H1 2019
- PoC study in PTSD to conclude around year-end 2018
- Additional LCM activity progressing

AAD: Agitation in Alzheimer’s disease; PoC: Proof of Concept; PTSD: Post-Traumatic Stress Disorder; LCM: Life-Cycle Mgmt.

Lundbeck’s share of revenue. Note: Outside North America, Rexulti has only been launched in Australia

Source: Symphony Health Solutions/Bloomberg (monthly data ending 6/2018)
Abilify Maintena grew 16% to DKK 771 million in H1 2018 – in local currencies the growth was 22%

- **Europe** and **International Markets** grew 19% (21% in L.C.) combined to DKK 446 million
- **North America** up 12% (24% in L.C.) to DKK 325 million
- Growth driven by Australia, Canada, France, Spain and the U.S.
- Largest markets are Australia, Canada, France, Spain and the U.S.
- Market share increasing - >20% volume share (LAI retail) in most markets
- **Total LAI market** reached USD 2.2 billion (+13%) in H1 2018

LAI: Long-acting injectable anti-psychotics

*) Based on quarterly reports from Lundbeck, Otsuka, Alkermes and Johnson & Johnson
U.S. neurology products, Northera and Onfi, continue to show solid growth in local currency

**Northera**
- Up 16% (30% in L.C.) to DKK 849 million in H1 2018
- Northera impacted by seasonal swings in demand
- Expected continued growth

**Onfi**
- Up 19% (34% in L.C.) to DKK 1,762 million in H1 2018
- Expected to grow until generic clobazam is introduced, expectedly in Q4 2018
Maintaining strong cost focus while also investing in the business

- **Total costs** down 5% while growing topline by 9% in H1 2018
- **EBITDA margin** of 38.2% vs. 31.2% in H1 2017
- **EBIT margin** of 32.4% vs. 24.3% in H1 2017
- **COS%**: Expected to show continued improvements vs. 2017
- **S&D%**: Stable or modest additional improvements vs. 2017
- **G&A%**: Stable or modest additional improvements vs. 2017
- **R&D%**: Slightly increasing vs. 2017 depending on project execution

*) Data adjusted for Other operating items, net
**Strong growth in earnings**

- Significant negative impact from FX reducing revenue growth
- Growth for all key products and in all regions in L.C.
- EPS growth of 83%
- Significant EPS improvement driven by
  - Solid revenue growth
  - Strong improvement of profitability
  - Reduced tax rate as the U.S. tax reform has decreased the group tax rate from 40% in H1 2017 to 27%

### Financial results

<table>
<thead>
<tr>
<th></th>
<th>DKKm</th>
<th>H1.18</th>
<th>H1.17</th>
<th>∆%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>9,288</td>
<td>8,494</td>
<td></td>
<td>9%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>81.6%</td>
<td>76.9%</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>3,006</td>
<td>2,061</td>
<td>46%</td>
<td></td>
</tr>
<tr>
<td>EBIT margin</td>
<td>32.4%</td>
<td>24.3%</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Core EBIT</td>
<td>3,578</td>
<td>2,500</td>
<td>43%</td>
<td></td>
</tr>
<tr>
<td>Net profit</td>
<td>2,198</td>
<td>1,195</td>
<td>84%</td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>11.07</td>
<td>6.05</td>
<td>83%</td>
<td></td>
</tr>
</tbody>
</table>

### Revenue

(reported vs. L.C)

<table>
<thead>
<tr>
<th></th>
<th>DKKm</th>
<th>H1.18</th>
<th>∆ DKKm</th>
<th>∆% L.C.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>9,288</td>
<td>+794</td>
<td>+14%</td>
<td></td>
</tr>
<tr>
<td>- Abilify Maintena</td>
<td>771</td>
<td>+104</td>
<td>+22%</td>
<td></td>
</tr>
<tr>
<td>- Brintellix/Trintellix</td>
<td>999</td>
<td>+205</td>
<td>+36%</td>
<td></td>
</tr>
<tr>
<td>- Northera</td>
<td>849</td>
<td>+115</td>
<td>+30%</td>
<td></td>
</tr>
<tr>
<td>- Onfi</td>
<td>1,762</td>
<td>+285</td>
<td>+34%</td>
<td></td>
</tr>
<tr>
<td>- Rexulti</td>
<td>752</td>
<td>+165</td>
<td>+44%</td>
<td></td>
</tr>
<tr>
<td>North America</td>
<td>5,287</td>
<td>+77</td>
<td>+14%</td>
<td></td>
</tr>
<tr>
<td>Int. Markets</td>
<td>1,920</td>
<td>+51</td>
<td>+11%</td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>1,518</td>
<td>+87</td>
<td>+7%</td>
<td></td>
</tr>
</tbody>
</table>
Strong cash flow generation and improved ROIC

- Cash flows from operating activities increased from DKK 1,217 million in H1 2017 to DKK 3,369 million in H1 2018.
- Acquisition of Prexton Therapeutics in Q1 impacts net cash flow by DKK 745 million.
- Dividend payout for 2017 increased to DKK 1.6 billion.
- ROIC increased from 26.6% in FY2017 to 53.2% in H1 2018.
2018 financial outlook revised

- Growth in all three regions in local currencies
- Continued growth for key products to outpace the decline from generic erosion
- Onfi revenue is expected to decline 40-50% compared to prior quarters in 2018
- Net financial items of DKK ±50 million expected in 2018
- No known additional one-off income and/or expenses
- Unchanged currencies from end-July 2018

### 2018 financial guidance

<table>
<thead>
<tr>
<th></th>
<th>DKKbn</th>
<th>2016</th>
<th>2017</th>
<th>Previous 2018 guidance</th>
<th>Revised 2018 guidance</th>
<th>~Δ% (y/y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td></td>
<td>15.6</td>
<td>17.2</td>
<td>17.2-18.0</td>
<td>17.6-18.0</td>
<td>2-5%</td>
</tr>
<tr>
<td>EBIT</td>
<td></td>
<td>2.3</td>
<td>4.4</td>
<td>4.8-5.2</td>
<td>4.9-5.2</td>
<td>11-18%</td>
</tr>
<tr>
<td>Implied EBIT margin</td>
<td>14.7%</td>
<td>25.6%</td>
<td>~27-30%</td>
<td>~27-30%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Tax rate</td>
<td></td>
<td>43.9%</td>
<td>38.7%</td>
<td>26-28%</td>
<td>26-28%</td>
<td>-</td>
</tr>
</tbody>
</table>
The value of Lundbeck’s R&D pipeline is increasing

- **Brexpiprazole**: Approved by the European Commission and in Switzerland
- **Vortioxetine**: Strong pivotal data in Japanese patients
- **Lu AF35700**: Finished recruiting in DAYBREAK I
- **Ability Maintena 2-month**: Single dose study finished now moving into multi-dose study
- **Lu AF76432**: Phase I initiated in May 2018 (schizophrenia)
- **Lu AF28996**: Phase I initiated in June 2018 (Parkinson’s)
- **Lu AF82422**: Phase I initiated in August 2018 (Parkinson’s)
Major clinical programme ongoing with Lu AF35700 – first results to be reported in Q4 2018

Lu AF35700
- For the treatment of treatment-resistant schizophrenia (TRS) which represents a major unmet medical need
- Antagonist at dopaminergic, serotonergic, and α adrenergic receptors. Unlike all currently available antipsychotics, Lu AF35700 has higher affinity for the human dopamine D<sub>1</sub> receptor than it has for the human dopamine D<sub>2</sub> receptor

Clinical studies in TRS
- **DAYBREAK I** evaluates the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (n = 964) (NCT02717195)
- **ANEW** evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease or late-in-disease treatment-resistant schizophrenia (n = 285) (NCT03230864)

Supportive clinical studies
- Study to evaluate the pharmacokinetics of Lu AF35700 after a single dose tablet to subjects with renal impairment and compare that with healthy subjects (n = 32) (NCT03241147)
- Study to investigate the effect of multiple doses of the strong P450 enzyme inhibitor itraconazole on the pharmacokinetics of Lu AF35700 in healthy subjects (n = 23) (NCT03103646)
- Study to establish bioequivalence of Lu AF35700 between the clinical formulation and the commercial formulation for three tablet strengths; 5, 10 and 20 mg (n = 90) (NCT03394482)

Upcoming events
- Communicate headline results from first study (**DAYBREAK I**) in the pivotal programme during Q4 2018
### Comprehensive LCM programme ongoing for brexpiprazole for further product value expansion

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brexpiprazole</td>
<td>Several clinical programmes ongoing to address unmet medical needs and aiming for product value maximation</td>
</tr>
</tbody>
</table>
| Bipolar I disorder   | Two studies to demonstrate the efficacy in acute treatment of manic episodes, with or without mixed features, in subjects with a diagnosis of Bipolar I disorder (n = 320 in both studies) (NCT03257865, NCT03259555)  
|                      | Evaluating the safety and tolerability in the treatment of subjects with Bipolar I disorder (n = 384) (NCT03287869)                                                                                              |
| Agitation in Alzheimer’s | Programme to compare the efficacy of 2 doses (2 mg and 3 mg) of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer’s type (n = 225) (NCT03548584, NCT03594123 (12-week extension study)) |
| PTSD                 | Evaluating the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy (Zoloft) in adults with PTSD (n = 332) (NCT03033069)                                             |
| Adolescents          | To determine the safety and efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia (n = 387) (NCT03198078)  
|                      | To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia (n = 350) (NCT03238326)                                                                       |
| Upcoming events      | Headline results from the PoC study in PTSD to be reported in Q1 2019  
|                      | Headline results from the pivotal programme in Bipolar mania to be reported in Q1 2019                                                                                                                      |
Lu AF20513 to enter proof of concept-study during H1 2019

**Lu AF20513**
- An active vaccine inducing high affinity polyclonal antibodies that target beta-amyloid ("Abeta"), for the potential injectable prevention of progression of Alzheimer's dementia

**Ongoing activities**
- Open label study to determine if multiple immunizations with Lu AF20513 is tolerable and safe in patients with mild Alzheimer's disease (n = 50) (NCT02388152)
- Investigating if subjects are generating antibodies

**Upcoming events**
- PoC study expected to commence in H1 2019
Foliglurax is an innovative and highly attractive phase II compound being developed for symptomatic treatment of Parkinson’s disease

**Foliglurax**

- A small-molecule positive allosteric modulator of group III metabotropic glutamate receptor 4 (mGluR4 PAM), for the potential oral treatment of Parkinson's disease

**Ongoing activities**

- Phase II proof of concept study in subjects with Parkinson’s treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia (n = 165) (NCT03162874)

**Upcoming events**

- PoC study expected to finalize in Q3 2019
Pipeline progressing with further newsflow expected in the next 12 months

- **Lu AF35700: Data from first pivotal study**
  - Headline results from *DAYBREAK I* (Q4 2018)

- **Brexpiprazole: Data from life cycle management programme**
  - PoC headline results in PTSD (Q1 2019)
  - Pivotal data in bipolar mania (Q1 2019)

- **Trintellix sNDA**
  - The U.S. FDA accepted an sNDA for the drug to treat MDD in patients with treatment-emergent sexual dysfunction in February 2018. PDUFA is set to 21 October 2018

- **Lu AF20513: Entering clinical Proof of Concept study**
  - Based on the data from phase I, Lundbeck intends to advance Lu AF20513 into a phase II clinical study in Alzheimer’s disease patients (H1 2019)

- **Foliglurax: Clinical proof of concept**
  - Headline results from PoC study (Q3 2019)
Thank you!